Valeant (VRX) Approaching Lenders to Determine Demands for Waiving a Default
March 18, 2016 at 13:27 PM EDT
Valeant Pharmaceuticals (VRX) shares are trading lower by 9.35% to $26.92 following a Bloomberg report saying the drugmaker’s bankers are trying to determine demands of lenders for waiving a default caused by the co.’s delayed earnings filing. The report also said lenders may seek concessions including higher interest rates, a one-time fee, and early repayment […] View the full post at: Valeant (VRX) Approaching Lenders to Determine Demands for Waiving a Default Related posts: Commercial Mortgage Default Rates May Rise to the Highest in 17 Years Goldman Rejects Shareholder Demands on Compensation Fidelity Discloses 14.97% stake in Ariad
